Inspire Medical Systems (INSP)
(Delayed Data from NYSE)
$126.10 USD
+1.56 (1.25%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $126.01 -0.09 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth D Momentum B VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
INSP 126.10 +1.56(1.25%)
Will INSP be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for INSP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for INSP
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
Butterfly Network, Inc. (BFLY) Reports Q2 Loss, Misses Revenue Estimates
INSP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Doximity (DOCS) Reports Next Week: Wall Street Expects Earnings Growth
Can Sustained Product Demand Drive HIMS Stock Before Q2 Earnings?
Inspire Medical Systems (INSP) Expected to Beat Earnings Estimates: Should You Buy?
Other News for INSP
Uncovering Potential: Inspire Medical Systems's Earnings Preview
Inspire Medical Systems Q2 2025 Earnings Preview
Baron Discovery Fund Q2 2025 Commentary
TimesSquare Global Small Cap Strategy Q2 2025 Commentary
Apnimed says sleep apnea drug meets primary endpoint in Phase 3 trial